John McBroom, MD
Gynecologic Oncology · Naples, FLNPI 1568439768
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $138,359 of the $186,594 with a category attached, or 74.1%. 23 manufacturers reported payments, led by GSK at 49.0% of the total. Reporting peaked in 2022 at $55,790 and has fallen 57.4% since, to $23,777 in 2025. Among gynecologic oncology clinicians in FL with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 191 payments — averaging $976.93 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$92K
- AbbVie$45K
- Tesaro, Inc.$26K
- Clovis Oncology, Inc.$18K
- AstraZeneca$4K
- Medical Device Business Services, Inc.$1K
- plus $1K from 17 others
Across 2 payments — averaging $21,300 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Merck$43K
What the payments were for
- Consulting fees$28,00315%
- Speaking & faculty fees$138,35974%
- Travel & lodging$15,0678%
- Food & beverage$5,0453%
- Education$1210%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 48 | $91,503 |
| AbbVie | 30 | $45,062 |
| Tesaro, Inc. | 34 | $26,090 |
| Clovis Oncology, Inc. | 23 | $17,701 |
| AstraZeneca | 8 | $3,565 |
| Medical Device Business Services, Inc. | 7 | $1,250 |
| Pfizer | 4 | $276 |
| Eisai Inc. | 3 | $249 |
| Amgen | 8 | $173 |
| Caris MPI, Inc. | 2 | $116 |
| Johnson & Johnson | 4 | $111 |
| Seagen Inc. | 1 | $100 |
| Myriad Genetic Laboratories, Inc. | 1 | $97 |
| Merck | 6 | $97 |
| Genentech USA, Inc. | 4 | $57 |
| Verastem, Inc. | 1 | $26 |
| Aspira Women's Health Inc | 1 | $24 |
| Fennec Pharmaceuticals, Inc. | 1 | $21 |
| Conmed Corporation | 1 | $17 |
| Kyowa Kirin, Inc. | 1 | $17 |
| Bayer | 1 | $16 |
| Helsinn Therapeutics (U.S.), Inc. | 1 | $15 |
| Coopersurgical, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$186,594 in reported general payments places this provider in the 90th percentile of 117 gynecologic oncology providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Oxybutynin Chloride ErOxybutynin Chloride | 11 | $0 |
Paid to pharmacies, not to this prescriber.
Other gynecologic oncology in Naples
- Bradley MonkWest Palm Beach$2.5M
- Martin MartinoJacksonville$957K
- Brian SlomovitzFort Lauderdale$519K
- Ricardo EstapeMiami$457K
- Robert HollowayOrlando$432K
- Shelly SewardOrlando$349K
- Edward GrendysFort Myers$341K
- Jonathan BlackMiramar$329K
- Nathalie McKenzieOrlando$223K
- Troy GatcliffeMiami$172K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.